Timothy Coté (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Timothy Coté" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

1^st place

2^nd place

2^nd place

4^th place

4^th place

2semanticscholar.org

11^th place

8^th place

895^th place

692^nd place

447^th place

338^th place

155^th place

138^th place

low place

7,595^th place

621^st place

380^th place

1oxfordjournals.org

1,389^th place

2,996^th place

1drugstorenews.com

low place

low place

1surgeongeneral.gov

low place

low place

low place

low place

1pharmaceutical-technology.com

low place

low place

1coteorphan.com

low place

low place

low place

low place

biospace.com

"Former FDA Official Tim Cote JoinsEmmaus Medical Inc as Regulatory Advisor".

coteorphan.com

"Home". Archived from the original on 2016-07-06. Retrieved 2016-06-23.

doi.org

Torres, Christian (1 March 2010). "Rare opportunities appear on the horizon to treat rare diseases". Nat Med. 16 (3): 241. doi:10.1038/nm0310-241. PMID 20208483. S2CID 1332461.
Coté, Timothy R.; Xu, Kui; Pariser, Anne R. (1 December 2010). "Accelerating orphan drug development". Nat Rev Drug Discov. 9 (12): 901–902. doi:10.1038/nrd3340. PMID 21119719. S2CID 43668080.
Xu, Kui; Coté, Timothy R. (1 July 2011). "Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases". Brief Bioinform. 12 (4): 341–345. doi:10.1093/bib/bbr006. PMID 21357612 – via bib.oxfordjournals.org.

drugstorenews.com

"Cote named as FDA director of orphan product development". Archived from the original on 2016-08-13. Retrieved 2016-06-23.

fda.gov

fda.gov

Commissioner, Office of the. "2007 - FDA Appoints Coté to Head Orphan Products Development Office". Food and Drug Administration. Archived from the original on July 10, 2009.

accessdata.fda.gov

"Search Orphan Drug Designations and Approvals".

glassdoor.com

"Coté Orphan Consulting Reviews". 20 March 2022.

linkedin.com

nih.gov

pubmed.ncbi.nlm.nih.gov

Torres, Christian (1 March 2010). "Rare opportunities appear on the horizon to treat rare diseases". Nat Med. 16 (3): 241. doi:10.1038/nm0310-241. PMID 20208483. S2CID 1332461.
Coté, Timothy R.; Xu, Kui; Pariser, Anne R. (1 December 2010). "Accelerating orphan drug development". Nat Rev Drug Discov. 9 (12): 901–902. doi:10.1038/nrd3340. PMID 21119719. S2CID 43668080.
Xu, Kui; Coté, Timothy R. (1 July 2011). "Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases". Brief Bioinform. 12 (4): 341–345. doi:10.1093/bib/bbr006. PMID 21357612 – via bib.oxfordjournals.org.

oxfordjournals.org

bib.oxfordjournals.org

Xu, Kui; Coté, Timothy R. (1 July 2011). "Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases". Brief Bioinform. 12 (4): 341–345. doi:10.1093/bib/bbr006. PMID 21357612 – via bib.oxfordjournals.org.

pharmaceutical-technology.com

"Since July 2011, Timothy Cote MD MPH has served half the time as the Chief Medical Officer for the National Organization for Rare Disorders (NORD) and the other half as Professor of Regulatory Practice for the Keck Graduate Institute (KGI) in Claremont, California. Prior to these appointments he was Director of FDA's Office of Orphan Products Development for four years. - Image - Pharmaceutical Technology".

phrma.org

"#PhRMA12 Conversations: Dr. Tim Cote - PhRMA".

semanticscholar.org

api.semanticscholar.org

Torres, Christian (1 March 2010). "Rare opportunities appear on the horizon to treat rare diseases". Nat Med. 16 (3): 241. doi:10.1038/nm0310-241. PMID 20208483. S2CID 1332461.
Coté, Timothy R.; Xu, Kui; Pariser, Anne R. (1 December 2010). "Accelerating orphan drug development". Nat Rev Drug Discov. 9 (12): 901–902. doi:10.1038/nrd3340. PMID 21119719. S2CID 43668080.

surgeongeneral.gov

"Meeting Our Nation's Important Public Health Challenges: Transformation of the Public Health Service Commissioned Corps, Testimony Before the Committee on Government Reform, October 30, 2003". Archived from the original on August 28, 2016. Retrieved June 23, 2016.

tufts.edu

csdd.tufts.edu

"Archived copy" (PDF). csdd.tufts.edu. Archived from the original (PDF) on 11 June 2010. Retrieved 17 January 2022.{{cite web}}: CS1 maint: archived copy as title (link)

web.archive.org

"Archived copy" (PDF). csdd.tufts.edu. Archived from the original (PDF) on 11 June 2010. Retrieved 17 January 2022.{{cite web}}: CS1 maint: archived copy as title (link)
Commissioner, Office of the. "2007 - FDA Appoints Coté to Head Orphan Products Development Office". Food and Drug Administration. Archived from the original on July 10, 2009.
"Cote named as FDA director of orphan product development". Archived from the original on 2016-08-13. Retrieved 2016-06-23.
"Meeting Our Nation's Important Public Health Challenges: Transformation of the Public Health Service Commissioned Corps, Testimony Before the Committee on Government Reform, October 30, 2003". Archived from the original on August 28, 2016. Retrieved June 23, 2016.
"Home". Archived from the original on 2016-07-06. Retrieved 2016-06-23.

zenodo.org

Coté, Timothy R.; Xu, Kui; Pariser, Anne R. (1 December 2010). "Accelerating orphan drug development". Nat Rev Drug Discov. 9 (12): 901–902. doi:10.1038/nrd3340. PMID 21119719. S2CID 43668080.